Parke-Davis has reformulated the Dye-Free version
of Benadryl so that the concentration is the same as
the Childrens' Allergy Liquid.
· FDA is warning consumers about "Skin-Cap" products
from Spain for the treatment of dandruff or psoriasis.
· New requirements for direct to consumer advertising
via broadcast media were announced last week by FDA.
Excedrin formulations are available both with and
new T-channel calcium blocker, has some important drug
· Clarification may be needed when Etopophos®
(etoposide phosphate) is prescribed to learn if the
dose is being expressed as the salt or the active moiety.
· Incidentally, the supplemental listing for etoposide
phosphate in Facts and Comparisons states that 119.3
mg EtopophosÒ is equivalent to 100 mg etoposide. However,
as noted in the package insert, 113.6 mg Etopophos is
equivalent to 100 mg etoposide. Using the incorrect
equivalency in Facts and Comparisons could result in
a 5% error in dosing if the prescriber writes an order
based on etoposide phosphate. According to Facts and
Comparisons editors, the listing should have stated
"119.3 mg etoposide phosphate diethanolate." The diethanolate
is removed during lyophilization. In future updates,
the listing will simply state "113.6 mg etoposide phosphate
is equivalent to 100 mg etoposide."